Tailoring Risperidone-Loaded Glycethosomal In Situ Gels Using Box–Behnken Design for Treatment of Schizophrenia-Induced Rats via Intranasal Route

    October 2023 in “ Pharmaceutics ”
    Marwa H. Abdallah, Hemat El‐Sayed El‐Horany, Hanan M. El-Nahas, Tarek Ibrahim
    TLDR The new nasal gel for schizophrenia improved drug absorption and brain effects in rats.
    The study developed and optimized risperidone-loaded glycethosomal in situ gels for intranasal delivery to treat schizophrenia in rats, using the Box–Behnken Design. The optimized gel formulation, containing 20% poloxamer 407 and 1% hydroxypropyl methyl cellulose-K4M, demonstrated improved bioavailability, with an eight-fold increase compared to a control gel and a three-fold increase compared to a marketed tablet. The gel showed enhanced neuroprotective, antioxidant, and anti-inflammatory effects, significantly improving dopamine and serotonin levels in the hippocampus of schizophrenia-induced rats. The study suggests that this intranasal delivery method could be a promising alternative to oral therapy for schizophrenia patients.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results